Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: A randomized controlled trial

Archives of Internal Medicine

Volumn 167, Issue 2, 2007, Pages 148-154

  Hurwitz, Barry E ^a,b,d,e   Klaus, Johanna R ^a   Llabre, Maria M ^a,d   Gonzalez, Alex ^a   Lawrence, Peter J ^a   Maher, Kevin J ^a,b   Greeson, Jeffrey M ^d   Baum, Marianna K ^c   Shor Posner, Gail ^c   Skyler, Jay S ^a,b   Schneiderman, Neil ^a,b,c,d,e  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d Department of Biology   (United States)

^e University of Miami College of Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CALCIUM PHOSPHATE DIBASIC; PLACEBO; PROTEINASE INHIBITOR; SELENIUM; SELENOMAX; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG USE; ETHNICITY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MULTIVARIATE ANALYSIS; SELENIUM; VIRAL LOAD;

EID: 33846447783     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.2.148     Document Type: Article

References (48)

1. Rayman MP. The importance of selenium to human health. Lancet. 2000;356:233-241.
2. Makela AL, Nanto V, Makela P, Wang W. The effect of nationwide selenium enrichment of fertilizers on selenium status of healthy Finnish medical students living in south western Finland. Biol Trace Elem Res. 1993;36:151-157.
3. Tan J, Zhu W, Wang W, et al. Selenium in soil and endemic diseases in China. Sci Total Environ. 2002;284:227-235.
4. van Lettow M, Harries AD, Kumwenda JJ, et al. Micronutrient malnutrition and wasting in adults with pulmonary tuberculosis with and without HIV coinfection in Malawi. BMC Infect Dis. 2004;4:61.
5. Dworkin BM. Selenium deficiency in HIV infection and the acquired immunodeficiency syndrome (AIDS). Chem Biol Interact. 1994;91:181-186.
6. Baum MK, Shor-Posner G, Lai S, et al. High risk of HIV-related mortality is associated with selenium deficiency. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:370-374.
7. Campa A, Shor-Posner G, Indacochea F, et al. Mortality risk in selenium-deficient HIV-positive children. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:508-513.
8. Singhal N, Austin J. A clinical review of micronutrients in HIV infection. J Int Assoc Physicians AIDS Care (Chic Ill). 2002;1:63-75.
9. Mantero-Atienza E, Sotomayer MG, Shor-Posner G, et al. Selenium status and immune function in asymptomatic HIV-1 seropositive men. Nutr Res. 1991;11:1237-1250.
10. Shor-Posner G, Miguez MJ, Pineda LM, et al. Impact of selenium status on the pathogenesis of mycobacterial disease in HIV-1-infected drug users during the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:169-173.
11. Kupka R, Msamanga GI, Spiegelman D, et al. Selenium status is associated with accelerated HIV disease progression among HIV-1-infected pregnant women in Tanzania. J Nutr. 2004;134:2556-2560.
12. Hori K, Hatfield D, Maldarelli F, Lee BJ, Clouse KA. Selenium supplementation suppresses tumor necrosis factor alpha-induced human immunodeficiency virus type 1 replication in vitro. AIDS Res Hum Retroviruses. 1997;13:1325-1332.
13. Clark LC, Combs GF Jr, Turnbull BW, et al; Nutritional Prevention of Cancer Study Group. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA. 1996;276:1957-1963.
14. Slish JC, Catanzaro LM, Ma Q, et al. Update on the pharmacokinetic aspects of antiretroviral agents. Curr Pharm Des. 2006;12:1129-1145.
15. Jain R, Clark NM, Diaz-Linares M, Grim SA. Limitations of current antiretroviral agents and opportunities for development. Curr Pharm Des. 2006;12:1065-1074.
16. Little SJ. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
17. Dieleman JP, Jambroes M, Gyssens IC, et al; ATHENA Study Group. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy: the ATHENA cohort. AIDS. 2002;16:737-745.
18. Hurwitz BE, Klimas NG, Llabre MM, et al. HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk: role of protease inhibitor exposure. Cardiovasc Toxicol. 2004;4:303-316.
19. Broome CS, McArdle F, Kyle JA, et al. An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status. Am J Clin Nutr. 2004;80:154-162.
20. Kiremidjian-Schumacher L, Roy M, Wishe HI, et al. Supplementation with selenium and human immune cell functions, II: effect on cytotoxic lymphocytes and natural killer cells. Biol Trace Elem Res. 1994;41:115-127.
21. Folstein MF, Folstein SE, McHugh P. "Mini-Mental State Exam": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
22. Chesney MA, Ickovics J, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the ACTG adherence instruments. AIDS Care. 2000;12:255-266.
23. Olson OE, Palmer IS, Cary EE. Modification of the official fluorometric method for selenium in plants. J Assoc Off Anal Chem. 1975;58:117-121.
24. Koh T-S, Benson TH. Critical re-appraisal of fluorometric method for determination of selenium in biological materials. J Assoc Off Anal Chem. 1983;66:918-926.
25. Kline RB. Principles and Practice of Structural Equation Modeling. New York, NY: Guilford Publications; 1998.
26. Ullman JB. Structural equation modeling. In: Tabachnick BG, Fidell LS, eds. Using Multivariate Statistics. 4th ed. Boston, Mass: Allyn & Bacon; 2001:653-771.
27. Hu L, Bentler PM. Cutoff criteria for fit indices in covariance structure analysis. Struct Equation Model. 1999;6:1-55.
28. Look MP, Rockstroh JK, Rao GS, et al. Serum selenium versus subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-1 infection. Biol Trace Elem Res. 1997;56:31-41.
29. Cirelli A, Ciardi M, de Simone C, et al. Serum selenium concentration and disease progress in patients with HIV infection. Clin Biochem. 1991;24:211-214.
30. Constans J, Sire S, Sergeant C, et al. Dilated cardiomyopathy and selenium deficiency in AIDS [in French]. Rev Med Interne. 1997;18:642-645.
31. Constans J, Pellegrin JL, Sergeant C, et al. Serum selenium predicts outcome in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:392.
32. Burbano X, Miguez-Burbano MJ, McCollister K, et al. Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants. HIV Clin Trials. 2002;3:483-491.
33. Hu G, Cassano PA. Antioxidant nutrients and pulmonary function: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Epidemiol. 2000;151:975-981.
34. Duffield AJ, Thomson CD, Hill KE, Williams S. An estimation of selenium requirements for New Zealanders. Am J Clin Nutr. 1999;70:896-903.
35. Rayman MP. The use of high-selenium yeast to raise selenium status: how does it measure up? Br J Nutr. 2004;92:557-573.
36. Hendricks KM, Laferriere R, Houser RF, Knox TA. Dietary intake in HIV-positive persons with and without malabsorption. Nutr Clin Care. 2005;8:37-43.
37. Hesketh JE, Villette S. Intracellular trafficking of micronutrients: from gene regulation to nutrient requirements. Proc Nutr Soc. 2002;61:405-414.
38. Gandhi RT, Walker BD. Immunologic control of HIV-1. Annu Rev Med. 2002;53:149-172.
39. Bautista AP. Free radicals, chemokines, and cell injury in HIV-1 and SIV infections and alcoholic hepatitis. Free Radic Biol Med. 2001;31:1527-1532.
40. Volk T, Hensel M, Schuster H, Kox WJ. Secretion of MCP-1 and IL-6 by cytokine stimulated production of reactive oxygen species in endothelial cells. Mol Cell Biochem. 2000;206:105-112.
41. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science. 1973;179:588-590.
42. Xu XM, Carlson BA, Grimm TA, et al. Rhesus monkey simian immunodeficiency virus infection as a model for assessing the role of selenium in AIDS. J Acquir Immune Defic Syndr. 2002;31:453-463.
43. Shisler JL, Senkevich TG, Berry MJ, Moss B. Ultraviolet-induced cell death blocked by a selenoprotein from a human dermatotropic poxvirus. Science. 1998;279:102-105.
44. Beck MA, Levander OA, Handy J. Selenium deficiency and viral infection. J Nutr. 2003;133:1463S-1467S.
45. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991;10:2247-2258.
46. Fawzi WW, Msamanga GI, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med. 2004;351:23-32.
47. Taylor EW, Cox AG, Zhao L, et al. Nutrition, HIV, and drug abuse: J Acquir Immune Defic Syndr. 2000;25:S53-S61.
48. McKenzie RC, Arthur JR, Beckett GJ. Selenium and the regulation of cell signaling, growth, and survival. Antioxid Redox Signal. 2002;4:339-351.